Clinical Trials Logo

Gastrointestinal Tumors clinical trials

View clinical trials related to Gastrointestinal Tumors.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06152757 Recruiting - Clinical trials for Gastrointestinal Tumors

BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors

Start date: October 9, 2023
Phase: Early Phase 1
Study type: Interventional

This study is an exploratory single-arm, open, modified "3+3" dose escalation study with BGT007H injection. Approximately 11 to 14 subjects with recurrent/refractory gastrointestinal tumors will be enrolled to evaluate the safety of BGT007H injection. Four dose levels were designed for this study: 1.0×10^8cells, 3.0×10^8cells, 1.0×10^9cells, and 3.0×10^9cells. The primary objective of this study was to evaluate the safety, tolerability and pharmacokinetic profile of BGT007H cell therapy in patients with recurrent/refractory digestive tract tumors, to determine the maximum tolerated dose or the best effective dose, and to initially evaluate the effectiveness of BGT007H cell products.

NCT ID: NCT06085365 Recruiting - Clinical trials for Gastrointestinal Tumors

Effects of Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors

Start date: July 24, 2023
Phase: Phase 3
Study type: Interventional

Evaluate the effects of Suyusu (immunonutrition) in postoperative adjuvant chemotherapy for gastrointestinal cancer patients. The main endpoint of the study was the incidence of chemotherapy related adverse reactions (including bone marrow suppression, nausea and vomiting, diarrhea, and mucositis) in patients after two cycles of chemotherapy. The secondary endpoint indicators were: quality of life score (EORTC-QLQ-C30), nutritional risk score (PG-SGA, NRS2002), nutritional assessment indicators, changes in immune microenvironment, analysis of psychological status, survival time (1-year progression free survival rate), treatment tolerance (dose intensity, rate of treatment interruption, delay), etc.

NCT ID: NCT05981235 Recruiting - Clinical trials for Gastrointestinal Tumors

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

Start date: December 14, 2023
Phase: Phase 1
Study type: Interventional

This is a FTiH, Phase 1 IIT to evaluate the safety, feasibility, cellular kinetics (CK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic CLDN18.2+ GI tumors.

NCT ID: NCT05262335 Recruiting - Clinical trials for Gastrointestinal Tumors

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)

ALTER-G-001
Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

This is an open, multi-cohort, multi-center, exploratory and phase II clinical trial. To evaluate the efficacy and safety Anlotinib combined with chemotherapy as first-line and maintenance therapy for Gastrointestinal Tumors with Unresectable Liver Metastases.

NCT ID: NCT04629326 Recruiting - Clinical trials for Gastrointestinal Tumors

PD-L1 Targeting Molecular Imaging of Solid Tumors

Start date: July 20, 2021
Phase: N/A
Study type: Interventional

The objective of the study is to constrcut a noninvasive approach WL12 PET/CT to detect the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-PD-1/L1 treatment.